CN104644769A - Application of traditional Chinese medicine composition in preparation of medicine for treating prostatitis - Google Patents
Application of traditional Chinese medicine composition in preparation of medicine for treating prostatitis Download PDFInfo
- Publication number
- CN104644769A CN104644769A CN201510066056.1A CN201510066056A CN104644769A CN 104644769 A CN104644769 A CN 104644769A CN 201510066056 A CN201510066056 A CN 201510066056A CN 104644769 A CN104644769 A CN 104644769A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- parts
- medicine composition
- group
- prostatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention belongs to the technical field of medicine and particularly relates to application of the traditional Chinese medicine composition in preparation of a medicine for treating prostatitis. The traditional Chinese medicine composition is prepared by performing alcohol extracting on the following raw materials: 6-10 parts of giant knot weed, 5-8 parts of plantain herb, 5-8 parts of glossy privet fruit, and 1-4 parts of beehive. The traditional Chinese medicine composition can be used for treating the prostatitis and has the advantages of rapid effect, short course of treatment, high cure rate and low toxic side effect, and also is simple in operation process, stable in medical effect and easy to popularize and apply.
Description
Technical field
The invention discloses the purposes of a kind of Chinese medicine composition in preparation treatment prostatitis medicine, belong to medical art.
Background technology
Prostatitis refers to the inflammation betiding prostata tissue.Refer to prostate specific and the active chronic inflammation caused by non-specific infection, thus the whole body caused or local symptom.Prostatitis is one of commonly encountered diseases of adult male.Although it is not a kind of direct life-threatening disease, have a strong impact on the quality of life of patient.Prostatitis patient accounts for Urologic Surgery Clinic patient's 8% ~ 25%, about has the male of 50% can be subject to prostatitic impact in certain period in life.Prostatitis can affect the adult male of all age group, and the adult male prevalence of the right side of fifty is higher.Prostatitis morbidity also may be relevant with season, diet, sexual activity, inflammation of genitourinary tracts, benign prostatic hyperplasia or lower urinary tract syndrome, occupation, socioeconomics and psychologic factors etc.
Prostatitis is divided into 4 kinds: I type (acute bacterial prostatitis) clinically: onset is anxious, shiver with cold, high heat can be shown as, with continuing and obvious lower urinary tract infection symptom, as frequent micturition, urgent micturition, dysurea, burning on urination, dysuria, urine retention, Posterior urethral, anus, perineal region falling inflation are uncomfortable.In blood and urine, quantity of leucocyte raises, positive bacterial culture.
II type (chronic bacterial prostatitis): the lower urinary tract infection symptom (as above) having recurrent exerbation, the persistent period was more than 3 months.
III type (chronic prostatitis): main manifestations is pelvis area pain, is found in the positions such as perineum, penis, crissum portion, urethra, pubis portion or lumbosacral region.Paruria can show as urgent micturition, frequent micturition, dysurea and nocturia and increase.Due to chronic pain obstinate, patients ' life quality declines, and may sexual disorders, anxiety, depression, insomnia, hypomnesis etc.
IV type (silent prostatitis): without subjective symptom, only about finding inflammation evidence during inspection in prostate.
At present, western medical treatment prostatitis often adopts antibiotics, to acute prostatitis treatment, adopt penicillin, streptomycin, ampicillin, pioneer's penicillin, etc. antibacterials treat; The medicines such as chronic bacterial prostatitis multiselect erythromycin, doxycycline, the first spiramycin of second are treated.Said medicine treatment all there is certain side effect, injure kidney, treatment cycle is long, unsatisfactory curative effect, and general antibacterials not easily enter prostata tissue, cause suffer from prostatitic patient be difficult to healing.
The prostatitis traditional Chinese medical science belongs to " essence turbid " category, on the whole its pathological factor be the smart room of damp and hot stagnation of blood stasis, and prolonged illness is " kidney qi virtual loss, the middle deficiency of vital energy are weak " then, and in the differentiation of pathological process, accompany stagnation of liver-QI, emotional factors plays important effect in pathogenic process more.So all can erection disturbance be there is in later stage chronic prostatitis.Otherwise some idiopathic sexual dysfunctions, constrain, drainage difficulty for a long time, become again the paathogenic factor causing chronic prostatitis.Therefore emphasize while Drug therapy, need psychological counseling be paid attention to, just can bring out the best in each other.Drug therapy should be noted shaking soothing the liver and the kidney invigorating and essence nourishing, clearing away heat-damp and promoting diuresis fit applications of withering.
Summary of the invention
Technical problem to be solved by this invention is the purposes of a kind of Chinese medicine composition in preparation treatment prostatitis medicine, and this Chinese medicine composition instant effect, short treating period, toxic and side effects are low.
The present invention solves by the following technical programs, the purposes of Chinese medicine composition in preparation treatment prostatitis medicine, described Chinese medicine composition comprises the raw material of following weight portion: Rhizoma Polygoni Cuspidati 6 ~ 10 parts, Herba Plantaginis 5 ~ 8 parts, Fructus Ligustri Lucidi 5 ~ 8 parts, 1 ~ 4 part, Nidus Vespae.
The parts by weight of the present invention to above-mentioned all taste Chinese medicine carry out preferably, preferred condition be after drug matching uses medicine to the enhancing of prostatitis treating effect.As a preferred embodiment of the present invention, Chinese medicine composition of the present invention obtains primarily of the raw material of following weight portion: Rhizoma Polygoni Cuspidati 7 parts, Herba Plantaginis 6 parts, Fructus Ligustri Lucidi 6 parts, 3 parts, Nidus Vespae.
In Chinese medicine composition described above, various Chinese medicinal components is all got its conventional agents area and is used as medicine.The mutual compatible combination of said medicine in the present invention, complements one another, and reaches the object of detumescence, antiinflammatory, has good curative effect to prostatitis, and people's dosage range of Chinese medicine composition of the present invention is 1mg ~ 50g/kgd.
In order to express Chinese medicine composition of the present invention better, Chinese medicine composition of the present invention can be prepared into oral formulations conventional clinically.Such as, the preparation such as powderous preparations, powder, pill, sublimed preparation, granule, oral liquid, syrup, tablet, capsule.Preferably, Chinese medicine composition of the present invention conveniently preparation technology be prepared into mixture, tablet, capsule.
The method preparing Chinese medicine composition of the present invention is as follows: each medical material getting above-mentioned components by weight percent, add the alcoholic solution of 75% concentration of 12 times of medical material gross weight, 65 DEG C of reflux, extract, 3 hours, filter, filtrate reduced in volume is to the extractum of relative density 1.25, this relative density is the testing result at 60 DEG C, and preparation after extract dry, to obtain final product.Those skilled in the art can technically prepare conventional Chinese medicine pharmaceutical dosage form clinically, as tablet, capsule etc. in this preparation method.
The prostatitic effect experiment data of traditional Chinese medicine composition for treating of the present invention:
(1) antiinflammatory action of Chinese medicine composition xylol induced mice inflammatory model of the present invention
Hydrocortisone has stronger anti-inflammatory activity, be synthetic be also naturally occurring glucocorticoid, after hydrocortisone enters cell, activate cytoplasmic receptor, nucleus is entered after allosteric, be combined with DNA response element, cause suppression or the induction of genetic transcription, the expression of inflammation related proteins is changed.
1, experimental technique:
40 KM mices, male and female half and half, body weight 28-32 gram, four groups are divided at random, i.e. dosage group in model control group, Chinese medicine high dose group, Chinese medicine, Chinese medicine low dose group, hydrocortisone group by body weight, often organize 10, each administration group mice gives following medicine respectively:
Model control group: gavage gives the normal saline of same volume;
Hydrocortisone group: gavage gives the hydrocortisone drug solution of 3mg/kg;
Chinese medicine high dose group: gavage gives 1.0g/kg embodiment 3 Chinese medicine composition, and Chinese medicine composition presses crude drug gauge;
Dosage group in Chinese medicine: gavage gives 0.5g/kg embodiment 3 Chinese medicine composition, and Chinese medicine composition presses crude drug gauge;
Chinese medicine low dose group: gavage gives 0.25g/kg embodiment 3 Chinese medicine composition, and Chinese medicine composition presses crude drug gauge.
Each administration group is administered once every day, successive administration 7d.Get dimethylbenzene 20 μ l after last administration, be applied to each mouse right ear.Get after 30 minutes and be respectively evenly applied to mouse right ear respectively by reagent 0.03 ml, auris dextra is put to death after 3.5 hours to dimethylbenzene, measures each group of mice left and right ear method of double differences.Ear method of double differences assay method: place cuts two ears along auricle baseline, lays auricle with 8mm card punch at the same position of left and right ear, weighs, the ear method of double differences=auris dextra sheet weight-left auricle weight.The ear method of double differences can be used as evaluates antiinflammatory index.
2, experimental result:
Measure the antiphlogistic effects that each experimental mice ear method of double differences evaluates each medication group medicine.Measurement result is in table 1.
Table 1 each experimental mice ear method of double differences compares
| Group | n | The ear method of double differences (mg) |
| Model control group | 10 | 8.22±1.16 |
| Hydrocortisone group | 10 | 4.46±1.52** |
| Chinese medicine high dose group | 10 | 2.82±1.64**# |
| Dosage group in Chinese medicine | 10 | 5.96±1.28* |
| Chinese medicine low dose group | 10 | 6.26±1.41* |
Compare with model control group, * P < 0.05; Compare with model control group, * * P < 0.01;
Compare with hydrocortisone group, #P < 0.05.
Result display gives hydrocortisone and Chinese medicine composition of the present invention all can obtain significant antiphlogistic effects, wherein, compared with model group, the antiphlogistic effects of Chinese medicine composition high dose group of the present invention and hydrocortisone group has pole significant difference, and Chinese medicine composition low dose group and middle dosage group have significant difference; Compared with hydrocortisone group, Chinese medicine composition high dose group has significant difference, and this shows that the high dose group antiphlogistic effects of Chinese medicine composition of the present invention will significantly be better than hydrocortisone group.
(2) Chinese medicine composition of the present invention is on the impact of rat urine volume
1, Applied Materials
Animal: SD rat 50, male and female half and half, body weight 180 ~ 200g.
Medicine: composite shi-wei tablet; The embodiment of the present invention 3 Chinese medicine composition; Normal saline.Medicine configures with distilled water on pretreatment, gastric infusion.
2, experimental technique
SD rat 50, is divided into 5 groups at random, often organizes 10.Before experiment, Rat Fast can't help water 12 hours.Press 2ml/100g body weight dose intraperitoneal injection of saline for each group, simultaneously gastric infusion.6 hours gastric infusions again, put into metabolic cage chamber pot 24 hours after administration immediately by rat, survey total volume of urine.Between organizing, significance detects.
Model control group: gavage gives the normal saline of same volume;
Composite shi-wei tablet group: gavage gives the composite shi-wei tablet drug solution of 0.1g/kg;
Chinese medicine high dose group: gavage gives 0.1g/kg embodiment 3 Chinese medicine composition, and Chinese medicine composition presses crude drug gauge;
Dosage group in Chinese medicine: gavage gives 0.05g/kg embodiment 3 Chinese medicine composition, and Chinese medicine composition presses crude drug gauge;
Chinese medicine low dose group: gavage gives 0.25g/kg embodiment 3 Chinese medicine composition, and Chinese medicine composition presses crude drug gauge.
3, experimental result: in table 2
Table 2 Chinese medicine composition of the present invention is on the impact of rat urine volume
| Grouping | Number of animals (only) | 24h urine volume (ml) |
| Model control group | 10 | 11.86±1.42 |
| Composite shi-wei tablet group | 10 | 14.45±1.56** |
| Chinese medicine low dose group | 10 | 13.54±1.72* |
| Dosage group in Chinese medicine | 10 | 14.02±1.58* |
| Chinese medicine high dose group | 10 | 15.69±1.24**# |
Compare with model control group, * P < 0.05; Compare with model control group, * * P < 0.01;
Compare with composite shi-wei tablet group, #P < 0.05.
Result shows: Chinese medicine composition group of the present invention and composite shi-wei tablet group obviously increase urine volume in rat upon administration 24h, have significant diuresis to Water l oad rat.Wherein, compared with model group, Chinese medicine composition high dose group of the present invention and composite shi-wei tablet group have pole significant difference, and Chinese medicine composition low dose group and middle dosage group have significant difference; Compared with composite shi-wei tablet group, Chinese medicine composition high dose group has significant difference, and this shows that the high dose group diuresis of Chinese medicine composition of the present invention will significantly be better than composite shi-wei tablet group.
(3) Chinese medicine capsules of the present invention treats prostatitic clinical data:
(1), this test patient provides by certain the People's Hospital of city, is provided with 100 and makes a definite diagnosis and suffer from prostatitis patient and participate in, be divided into matched group and experimental group, each 50 examples.System clinical treatment observation is carried out to prostate patient, all meets inclusion criteria, without exiting and reject case, its age 30-65 year.
(2), test medication: the capsule produced by the embodiment of the present invention 3 preparation technology, the crude drug content of capsule is 0.5g crude drug/g capsule.
(3), test method: experimental group patient oral capsule, every day 3 times, each 33 weeks is a course for the treatment of, treats 3 courses for the treatment of continuously.Matched group patient adopts the conventional medicine such as bactrim, erythromycin.
(4), judgment criteria
Cure: after terminating the course for the treatment of, symptom, sign disappear, and laboratory leading indicator is close normal after recovering;
Effective: after terminating the course for the treatment of, symptom, sign disappear substantially, and laboratory leading indicator also has clear improvement;
Effective: after terminating the course for the treatment of, symptom, sign alleviate, and laboratory leading indicator is also improved;
Invalid: after terminating the course for the treatment of, symptom, sign and other indexs are without obvious improvement.
(5), therapeutic outcome
| Project | Number of cases | Recovery from illness | Effective | Effectively | Invalid | Cure-remarkable-effectiveness rate | Total effective rate |
| Treatment group | 50 | 30 | 12 | 7 | 1 | 84.0% | 98.0% |
| Matched group | 50 | 26 | 9 | 10 | 5 | 70.0% | 90.0% |
By upper Biao Ke get, the cure-remarkable-effectiveness rate for the treatment of group is 84.0%, exceeds 14.0% than matched group, total effective rate is 98.0%, higher than matched group by 8.0%, therefore, treatment group clinical effectiveness, apparently higher than matched group, illustrates that Chinese medicine capsules of the present invention has significant curative effect to treatment prostatitis.
Now lift the symptom of three Clinic Case prostatitis patients and the effect after taking Chinese medicine capsules of the present invention:
1. Zhang, 36 years old, people from Haizhu District of Guangzhou city, little abdominal testis swelling, urine urgency-frequency was more than 2 years.Many hospitalizes, be diagnosed as prostatitis, treatment several months DeGrain, patient is very worried, the rear employing embodiment of the present invention 1 capsule, every day 3 times, each 3, within 3 weeks, be a course for the treatment of, successful after the course for the treatment of, disease alleviates gradually, cure after three courses for the treatment of, the symptom of little abdominal testis swelling, urine urgency-frequency disappears completely, existing 2 years so far, does not recur.
2. Zhao, 25 years old, people from Liwan, Guangzhou, urine urgency-frequency urine retention, lower abdomen femoribus internus pain more than 1 year, ache influence Working Life, be diagnosed as prostatitis, the rear employing embodiment of the present invention 2 capsule, every day 3 times, each 3, within 3 weeks, be a course for the treatment of, cure after two courses for the treatment of, urinate normal, urine urgency-frequency urine retention transference cure, lower abdomen and femoribus internus pain disappear.
3. Lee, 38 years old, people from Yuexiu District, Guangzhou, urine urgency-frequency, testis swelling 6 years, looked into lecithin about 30%, leukocyte 15-20/HP, is diagnosed as prostatitis.Treating in 6 years always, going the hospitalize of to too much home, DeGrain, spirit depressing.By taking the embodiment of the present invention 3 capsule, every day 3 times, each 33 weeks is a course for the treatment of, therapeutic effect through three courses for the treatment of is obvious, disease almost disappears, and cures again, urine urgency-frequency after two courses for the treatment of, the disease of testis swelling disappears completely, every inspection is all normal, lecithin about 70%, leukocyte < 10/HP.
In a word, Chinese medicine composition of the present invention is row adenitis aspect before the treatment, compared with prior art has following advantage:
1) compared with the chemotherapeutic agent of Current therapeutic, Chinese medicine composition of the present invention is natural pure Chinese medicinal preparation, untoward reaction and side effect significantly reduce, and Chinese medicine composition effect of the present invention is comprehensive, medication effect is better, significantly improve the compliance of prostatitis patient, and improve the quality of life of patient;
2) contain multi-medicament component in Chinese medicine composition of the present invention, action target spot is numerous, and efficiently solve prostatitic morbidity root, it serves the effect for the treatment of both the principal and secondary aspects of a disease to prostatitic therapeutic effect;
3) compatibility science of the present invention, curative effect is rapid, the advantage such as have instant effect, short treating period, cure rate is high, expense is little, and its operating procedure is easy, efficacy stability, be easy to apply.
Detailed description of the invention
Below will further illustrate the present invention by specific embodiment, but it should be appreciated by those skilled in the art that the specific embodiment of the invention and do not limit the present invention in any way.Take up an official post on basis of the present invention and how all fall within protection scope of the present invention with replacement.
eXAMPLE l, Chinese medicinal composition capsules agent of the present invention
Prescription: Rhizoma Polygoni Cuspidati 6 parts, Herba Plantaginis 5 parts, Fructus Ligustri Lucidi 5 parts, 1 part, Nidus Vespae.
Preparation method: each medical material getting above-mentioned components by weight percent, add the alcoholic solution of 75% concentration of 12 times of medical material gross weight, 65 DEG C of reflux, extract, 3 hours, filter, filtrate reduced in volume is to the extractum of relative density 1.25, and this relative density is the testing result at 60 DEG C, extractum vacuum drying, granulate, encapsulated and get final product.
embodiment 2, Chinese medicinal composition capsules agent of the present invention
Prescription: Rhizoma Polygoni Cuspidati 10 parts, Herba Plantaginis 8 parts, Fructus Ligustri Lucidi 8 parts, 4 parts, Nidus Vespae.
Preparation method: each medical material getting above-mentioned components by weight percent, add the alcoholic solution of 75% concentration of 12 times of medical material gross weight, 65 DEG C of reflux, extract, 3 hours, filter, filtrate reduced in volume is to the extractum of relative density 1.25, and this relative density is the testing result at 60 DEG C, extractum vacuum drying, granulate, encapsulated and get final product.
embodiment 3, Chinese medicinal composition capsules agent of the present invention
Component: Rhizoma Polygoni Cuspidati 7 parts, Herba Plantaginis 6 parts, Fructus Ligustri Lucidi 6 parts, 3 parts, Nidus Vespae.
Get each medical material of above-mentioned components by weight percent, add the alcoholic solution of 75% concentration of 12 times of medical material gross weight, 65 DEG C of reflux, extract, 3 hours, filter, filtrate reduced in volume is to the extractum of relative density 1.25, and this relative density is the testing result at 60 DEG C, extractum vacuum drying, granulates, encapsulated and get final product.
Below be only the preferred embodiment of the present invention, it should be pointed out that above-mentioned preferred implementation should not be considered as limitation of the present invention, protection scope of the present invention should be as the criterion with claim limited range.For those skilled in the art, without departing from the spirit and scope of the present invention, can also make some improvements and modifications, these improvements and modifications also should be considered as protection scope of the present invention.
Claims (5)
1. the purposes of Chinese medicine composition in preparation treatment prostatitis medicine, it is characterized in that, described Chinese medicine composition comprises the raw material of following weight portion: Rhizoma Polygoni Cuspidati 6 ~ 10 parts, Herba Plantaginis 5 ~ 8 parts, Fructus Ligustri Lucidi 5 ~ 8 parts, 1 ~ 4 part, Nidus Vespae.
2. purposes as claimed in claim 2, it is characterized in that, described Chinese medicine composition comprises the raw material of following weight portion: Rhizoma Polygoni Cuspidati 7 parts, Herba Plantaginis 6 parts, Fructus Ligustri Lucidi 6 parts, 3 parts, Nidus Vespae.
3. the purposes as described in as arbitrary in claim 1-2, it is characterized in that, the pharmaceutical formulation of described Chinese medicine composition is oral formulations.
4. purposes as claimed in claim 3, it is characterized in that, described oral formulations is capsule, tablet, powder, pill, granule or oral liquid.
5. purposes as claimed in claim 3, it is characterized in that, the preparation method of described oral formulations comprises the steps: each medical material getting above-mentioned components by weight percent, add the alcoholic solution of 75% concentration of 12 times of medical material gross weight, 65 DEG C of reflux, extract, 3 hours, filter, filtrate reduced in volume is to the extractum of relative density 1.25, this relative density is the testing result at 60 DEG C, is prepared into above-mentioned dosage form after extract dry.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510066056.1A CN104644769A (en) | 2015-02-07 | 2015-02-07 | Application of traditional Chinese medicine composition in preparation of medicine for treating prostatitis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510066056.1A CN104644769A (en) | 2015-02-07 | 2015-02-07 | Application of traditional Chinese medicine composition in preparation of medicine for treating prostatitis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104644769A true CN104644769A (en) | 2015-05-27 |
Family
ID=53236738
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510066056.1A Pending CN104644769A (en) | 2015-02-07 | 2015-02-07 | Application of traditional Chinese medicine composition in preparation of medicine for treating prostatitis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104644769A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108371676A (en) * | 2018-05-18 | 2018-08-07 | 广州暨南生物医药研究开发基地有限公司 | A kind of preparation method of the loyal gout Ultramicro-powder of tiger |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1931245A (en) * | 2006-09-06 | 2007-03-21 | 暨南大学 | Medicine for treating gouty arthritis and its prepn process and application |
| GB2497769A (en) * | 2011-12-21 | 2013-06-26 | qi ling Wang | A Chinese composition for the treatment of prostatitis |
-
2015
- 2015-02-07 CN CN201510066056.1A patent/CN104644769A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1931245A (en) * | 2006-09-06 | 2007-03-21 | 暨南大学 | Medicine for treating gouty arthritis and its prepn process and application |
| GB2497769A (en) * | 2011-12-21 | 2013-06-26 | qi ling Wang | A Chinese composition for the treatment of prostatitis |
Non-Patent Citations (2)
| Title |
|---|
| 张骅等: "虎杖临床应用研究进展", 《临床肺科杂志》 * |
| 肖奇国: "车前草新用途", 《大众卫生报》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108371676A (en) * | 2018-05-18 | 2018-08-07 | 广州暨南生物医药研究开发基地有限公司 | A kind of preparation method of the loyal gout Ultramicro-powder of tiger |
| CN108371676B (en) * | 2018-05-18 | 2021-06-29 | 广州暨南生物医药研究开发基地有限公司 | Preparation method of Ligustrum japonicum Thunb super-fine powder for gout |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101862351A (en) | Application of active parts of gallnut in preparing anti-ulcerative colitis medicine | |
| CN102225181B (en) | Medicament for treating benign prostatic hyperplasia disease and preparation method thereof | |
| CN100417402C (en) | Liposoluble traditional medicine bougie for treating acute and chronic prostatitis, and manufacturing technique thereof | |
| CN1327875C (en) | Chinese medicine formulation for treating chronic pelvic inflammation and its preparing method | |
| CN103599323B (en) | Traditional Chinese medicinal composition for treating prostatitis | |
| CN102579999B (en) | Medicine for treating carcinous fever and preparation method thereof | |
| CN105233150A (en) | Traditional Chinese medicine composition and application thereof | |
| CN102727716B (en) | Traditional Chinese medicine preparation for treating dampness-heat blood stasis type chronic prostatitis | |
| CN102579528B (en) | Medicine composition for preventing and curing prostatic diseases | |
| CN104644769A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating prostatitis | |
| CN103830288B (en) | Match certain herbaceous plants with big flowers extractive of general flavone and its production and use | |
| CN103768478A (en) | Traditional Chinese medicine composition for treating prostatitis and preparation method and application thereof | |
| CN102552440B (en) | Anti-asthmatic and anti-inflammatory medicament and preparation method and application thereof | |
| CN101919991B (en) | Drug composition for treating cervical cancer and preparation method thereof | |
| CN104337901A (en) | Chinese medicinal preparation for treating nonspecific cystitis and preparation method thereof | |
| CN100455309C (en) | Compound Chinese medicinal preparation for treating gynecological inflammation and preparation method thereof | |
| CN1327874C (en) | Chinese medicine formulation for treating chronic prostatitis and its preparing method | |
| CN109470788A (en) | A kind of method of quality control of FUKE QIANJIN PIAN | |
| CN101926859B (en) | Chinese medicinal composition | |
| CN102319391A (en) | Chinese medicinal soft capsule for treating uterine fibroid and preparation method thereof | |
| CN111714568B (en) | Preparation method of Fuyanxiao preparation | |
| CN102335284B (en) | Externally applied health care product for recovery of female cauliflower excrescence | |
| CN104435716A (en) | Traditional Chinese medicine composition for treating chronic bacterial prostatitis combined immunosuppression | |
| CN102961680B (en) | Traditional Chinese medicine preparation for treating gallstone and cholecystitis and preparation method thereof | |
| CN102579676B (en) | Chinese herbal compound preparation for treating chronic abacterial prostatitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150527 |
|
| RJ01 | Rejection of invention patent application after publication |